Table 2.
Influence of CT regimen on alopecia patients’ evaluation.
| Patients | Grade:0–1 alopecia (%) | Grade:2 alopecia (%) | Grade alopecia unknown (%) | |
|---|---|---|---|---|
| CAP | (N = 77) | |||
| TX Mono | 12 | 6 (50) | 5 (41.7) | 1 (8.3) |
| TX and AC | 64 | 11 (17.2) | 52 (81.2) | 1 (1.6) |
| sequence TX/AC | (N = 64) | |||
| TX followed by AC | 13 | 5 (38.5) | 8 (61.5) | 0 (0) |
| AC followed by TX | 25 | 5 (20) | 20 (80) | 0 (0) |
| TX AC simultaneously | 26 | 1 (3.85) | 24 (92.3) | 1 (3.85) |
| other | 1 | 1 (100) | 0 (0) | 0 (0) |
| NCAP | (N = 38) | |||
| TX Mono | 6 | 0 (0) | 6 (100) | 0 (0) |
| TX and AC | 32 | 0 (0) | 32 (100) | 0 (0) |
AC = anthracycline; CAP = intervention group; Mono = monotherapy; NCAP = control group; TX = taxane.